Hodgkin's Lymphoma [clinicaltrials_resource:a1292ac4a2dd5c8d13463a17a8303416]
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma [clinicaltrials:NCT00061672]Pegfilgrastim PBPC Mobilization Study [clinicaltrials:NCT00066092]Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies [clinicaltrials:NCT00143559]Trial of AVN-944 in Patients With Advanced Hematologic Malignancies [clinicaltrials:NCT00273936]clinicaltrials:NCT00276159clinicaltrials:NCT00283439Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) [clinicaltrials:NCT00285259]CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation [clinicaltrials:NCT00333190]clinicaltrials:NCT00352027Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma [clinicaltrials:NCT00358982]Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma [clinicaltrials:NCT00359892]Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma [clinicaltrials:NCT00428688]Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma [clinicaltrials:NCT00441818]clinicaltrials:NCT00481871phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients [clinicaltrials:NCT00496431]clinicaltrials:NCT00510315clinicaltrials:NCT00520130Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders [clinicaltrials:NCT00533923]clinicaltrials:NCT00626626Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies [clinicaltrials:NCT00670592]A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies [clinicaltrials:NCT00741871]clinicaltrials:NCT00784537Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat [clinicaltrials:NCT00791011]Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma Patients [clinicaltrials:NCT00792467]clinicaltrials:NCT00816959clinicaltrials:NCT00838955A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma [clinicaltrials:NCT00866333]Consolidation PET-based and Donor-based After Salvage Therapy in Patients With Hodgkin Lymphoma in Relapse or Refractory [clinicaltrials:NCT00879528]Positron Emission Tomography(PET) in Lymphoma Assessment [clinicaltrials:NCT00887718]clinicaltrials:NCT00896454Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma [clinicaltrials:NCT00901303]Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy [clinicaltrials:NCT00963495]Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma [clinicaltrials:NCT00967369]clinicaltrials:NCT00981760clinicaltrials:NCT00984165clinicaltrials:NCT01032148clinicaltrials:NCT01034163Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma [clinicaltrials:NCT01037478]Mozobil for Autologous Stem Cell Mobilization [clinicaltrials:NCT01164345]clinicaltrials:NCT01169636
condition [clinicaltrials_vocabulary:condition]
Hodgkin's Lymphoma [clinicaltrials_resource:a1292ac4a2dd5c8d13463a17a8303416]
Bio2RDF identifier
a1292ac4a2dd5c8d13463a17a8303416
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a1292ac4a2dd5c8d13463a17a8303416
identifier
clinicaltrials_resource:a1292ac4a2dd5c8d13463a17a8303416
title
Hodgkin's Lymphoma
@en
label
Hodgkin's Lymphoma [clinicaltrials_resource:a1292ac4a2dd5c8d13463a17a8303416]
@en